Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume – Time to Buy?

Shares of Pharvaris (NASDAQ:PHVS) saw unusually-high trading volume on Friday . Approximately 40,333 shares were traded during trading, an increase of 15% from the previous session’s volume of 34,958 shares.The stock last traded at $18.58 and had previously closed at $18.54.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer boosted their price target on Pharvaris from $38.00 to $42.00 and gave the stock an “outperform” rating in a research report on Friday, September 6th.

Pharvaris Stock Down 0.8 %

The stock has a market capitalization of $585.54 million, a P/E ratio of -6.57 and a beta of -3.17. The firm has a fifty day moving average price of $20.76 and a two-hundred day moving average price of $19.36.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC purchased a new position in Pharvaris in the third quarter worth about $106,000. Geode Capital Management LLC lifted its holdings in Pharvaris by 18.4% in the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after purchasing an additional 5,753 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris during the 3rd quarter worth approximately $57,000. Jane Street Group LLC purchased a new stake in shares of Pharvaris during the 3rd quarter worth approximately $526,000. Finally, Sphera Funds Management LTD. raised its holdings in shares of Pharvaris by 8.9% during the 3rd quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock worth $8,136,000 after acquiring an additional 36,027 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.